Peker, KevserPeker, Seydi Ali2025-01-212025-01-2120202636-8579https://doi.org/10.32322/jhsm.774520https://search.trdizin.gov.tr/tr/yayin/detay/500868https://hdl.handle.net/20.500.12587/22235Aim: The analgesic effect of ESPB for percutaneous nephrolithotomy have been reported in a few study. However there is not any study yet in terms of the effect of ESPB on the cost of anesthesia. The aim of the study is to evaluate the effect of ESPB on sevoflurane and opioid consumption and cost for percutaneous nephrolithotomy. Material and Method: The patients who underwent percutaneous nephrolithotomy were divided into two groups as ESPB group (Group B; N, 30) and non-ESPB group (Group K; N, 31) whether ESPB was performed or not in this prospective observatioanl study. Total consumption of sevoflurane, remifentanyl and total consumption of tramadol was recorded. Total consumption of sevoflurane, remifentanil and tramadol was multiplied by the unit price of the drug (milliliter and milligram) for determining cost estimation. Results: The total amount of remifentanil, sevoflurane and tramadol consumption were significantly lower in the Group B (respectively; p=0.009, p=0.001, p<0.001). The total remifentanil, sevoflurane and tramadol costs were found to be statistically significantly lower in the Group B (respectively: p=0.006, p=0.001, p<0.001). Conclusion: The ESPB is a cost-effective procedure and contributes to the multimodal anesthesia.eninfo:eu-repo/semantics/openAccessAnesteziÜroloji ve NefrolojiArticle3440941410.32322/jhsm.774520500868